GleamWall
中文EN

TOVX Theriva Biologics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 894158 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY66.7%
TTM EPS YoY-44.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.8%
ROA-28.0%
ROIC (approx.)-956.5%
Asset turnover—

Leverage & solvency

Liabilities / assets65.9%
Debt / equity0.00x
Current ratio1.21x
Interest coverage-138.77x

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio8.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$300,000—————
R&D expense$612,000$1.27M$355,000$1.13M$2.55M$1.95M$2.97M$2.89M
SG&A expense$923,000$2.03M$2.07M$931,000$1.89M$11.18M$1.45M$1.69M
Operating income-$1.53M-$3.29M-$2.13M-$2.06M-$4.44M-$13.13M-$4.42M-$4.58M
Interest expense$16,000$17,000$16,000$16,000$16,000$16,000$12,000—
Pretax income-$1.47M-$3.22M-$2.04M-$2.00M-$4.36M-$13.06M-$4.32M-$4.45M
Net income-$1.47M-$3.22M-$2.04M-$2.00M-$4.36M-$13.06M-$4.32M-$4.45M
EBITDA-$1.51M-$3.27M-$2.10M-$2.04M-$4.41M-$13.11M-$4.39M-$4.55M
EPS (basic)-0.03-0.07-0.05—-0.45-1.93-1.55—
EPS (diluted)-0.03-0.07-0.05—-0.45-1.93-1.55—
Weighted avg. shares (diluted)45.89M45.89M41.07M—9.68M6.75M2.78M—
Balance sheet
Cash & equivalents$8.47M$11.34M$14.43M$13.06M$7.53M$12.12M$10.01M$11.71M
Current assets$10.62M$13.67M$16.76M$17.47M$9.90M$14.74M$12.48M$16.28M
PP&E, net$155,000$173,000$194,000$222,000$249,000$258,000$253,000$270,000
Goodwill———————$0
Intangibles$18.96M$19.06M$19.23M$19.62M$19.61M$19.62M$18.08M$17.36M
Total assets$31.56M$34.86M$38.25M$38.24M$30.84M$35.83M$32.16M$35.35M
Current liabilities$8.78M$12.11M$10.26M$10.01M$11.00M$12.39M$8.15M$7.58M
Long-term debt———$1.67M———$92,000
Total debt———$1.67M———$92,000
Total liabilities$20.81M$22.67M$22.85M$22.86M$24.10M$25.21M$16.66M$16.29M
Shareholders' equity$10.75M$12.19M$15.40M$15.38M$6.74M$10.62M$15.50M$19.07M
Net debt———-$11.38M———-$11.61M
Shares outstanding45.89M45.89M45.89M35.69M10.30M9.06M2.78M2.78M
Cash flow statement
Operating cash flow-$2.86M-$3.08M-$2.46M-$2.88M-$4.32M-$4.71M-$4.76M-$4.69M
Capital expenditure$5,000——$0$19,000——$0
Free cash flow-$2.87M——-$2.88M-$4.34M——-$4.69M
Investing cash flow-$5,000——$0-$19,000——$0
Financing cash flow-$6,000-$14,000$3.87M$8.46M-$148,000$6.81M$3.07M$7,000
Depreciation & amortization$22,000$24,000$24,000$27,000$28,000$27,000$26,000$27,000
Stock-based compensation$144,000$135,000$135,000$153,000$228,000$173,000$100,000$162,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.